The Cannabis Stock Big Money Managers Are Quietly Buying

In Q3 2025 major quantitative trading firms and hedge funds accumulated Canopy Growth shares—Susquehanna added ~2.75M shares, Citadel ~2.7M, Millennium ~2.1M and D.E. Shaw ~1.9M—even as the company remains consistently unprofitable and blocked from the U.S. market. Shares rallied in December after President Trump urged DOJ to consider rescheduling marijuana to Schedule III but have since pulled back; whether the institutions sold into that weakness will become clearer with the next 13-F filings. Given regulatory uncertainty and weak fundamentals, recent positioning is a near-term driver but does not remove downside risks.

Analysis

Market structure: Big quantitative and hedge buyers (Susquehanna, Citadel, Millennium, D.E. Shaw) accumulating CGC in Q3 implies flow-driven liquidity support and higher sensitivity to short-term gamma and systematic strategies rather than fundamental conviction. Direct winners on a US rescheduling path are CGC and large Canadian LPs (potential M&A targets), plus US ancillary services and payments players; losers include municipal bond proxies and defensive staples if risk-on persists. The stock is binary: without US entry CGC remains valuation-constrained; with credible DOJ/Congress progress the market could re-rate quickly given scarcity of investable US-capable cannabis platforms.

Risk assessment: Tail risks include a federal policy reversal or a rescheduling that still blocks interstate commerce/banking, material equity dilution from Canopy to fund US entry, or a liquidity-driven unwind by quant funds producing 10–30% intraday moves. Time horizons: expect 1–5% headline-driven moves on 13F/news in days, 10–40% swing on regulatory headlines over weeks–months, and structural re-rating over 12–36 months if US access opens. Hidden dependencies: CGC’s upside hinges on banking access, state-level licensing transferability, and ability to execute M&A — not immediate revenue conversion.

Trade implications: For event-driven exposure use defined-risk option structures: buy 12–18 month LEAP call spreads on CGC (limit to 1–2% portfolio notional) to capture regulatory upside; sell short-dated covered calls or iron condors to monetize elevated IV if holding equity. Consider a relative-value pair: long CGC LEAPs vs short 50% notional in broad cannabis ETF (MJ) to isolate Canopy-specific US-entry optionality. Use 13F and DOJ/Congress calendar as trade triggers — add on confirmed regulatory language or if Q4 filings show >15% QoQ institutional accumulation.

Contrarian angles: Consensus underweights the optionality embedded in Canopy’s global brand and balance-sheet optionality (M&A currency) — quant buying may presage a liquidity backstop that dampens downside. The market may be overreacting to headline pullbacks: if CGC drops >25% absent negative fundamentals, that creates asymmetric risk/reward for LEAP call spreads; conversely, a rescheduling that preserves state restrictions could leave valuations materially compressed and trigger convertible/bond covenants. Historical parallels: biotech regulatory binary events and prior cannabis legalization headlines show fast re-rates followed by multi-quarter mean reversion; position sizing should assume 30–50% realized volatility.

Key Decisions for Investors

• Establish a defined-risk long position in CGC equal to 1.5% of portfolio via 12–18 month LEAP call spread (buy 20–30% OTM, sell 2 strikes higher) within 4 weeks to capture regulatory upside while capping premium; target >=3x payoff if federal rescheduling language is enacted within 12 months, stop-loss (cut premium exposure) if underlying equity declines >25% from entry.
• If next-month 13F filings show net institutional buys in CGC >15% QoQ or any of Susquehanna/Citadel/Millennium increase holdings by >1M shares each, add a tactical 0.75–1.0% portfolio tranche in the same LEAP structure within 5 trading days; if filings show net selling, reduce exposure to <=0.25% immediately.
• Implement a pair trade: long CGC LEAPs (1% notional) vs short 0.5% notional in broad cannabis ETF MJ to express Canopy-specific upside while hedging sector risk; rebalance weekly and widen the short if MJ outperforms CGC by >10% in 30 days.
• If holding CGC equity, sell 30–60 day covered calls to collect premium and reduce carry cost until a clear regulatory catalyst arrives; target implied volatility capture of at least 20% annualized above realized vol, and avoid writing >50% of position to keep upside optionality.